Publication | Open Access
Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis
34
Citations
16
References
2018
Year
No benefits were detected on treating ABPA in CF with omlaizumb. Monitoring the total IgE was not helpful. A prospective randomized double-blind study is needed.
| Year | Citations | |
|---|---|---|
Page 1
Page 1